WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位元堂藥業控股有限公司 *） 請注意， 閣下在填寫及交回非登記股東申請表格以索取本次公司通訊的印刷本後，即表示 閣下確認選擇 收取本公司所有日後公司通訊（2「公司通訊」）的印刷本。 倘 閣 下 對 本 通 知 有 任 何 疑 問，請 致 電 香 港 股 份 過 戶 登 記 分 處 諮 詢 熱 線(852) 2980 1333查 詢，辦 公 時 間 為 星期一至星期五（香港公眾假期除外）上午九時正至下午六時正。 （於百慕達註冊成立之有限公司） （股份代號：897） 各位非登記股東1： 於本公司網站刊登公司通訊之通知 謹此通知 閣下，Wai Yuen Tong Medicine Holdings Limited（位元堂藥業控股有限公司*）（「本公司」）之下述公司 通 訊（「本次公司通訊」）之英文及中文版本，現已於本公司網站www.wyth.net及香港聯合交易所有限公司（「聯 交 所」）網 站www.hkexnews.hk登載： 截至二零二五年九月三十日止六個月的中期報告 請 於 本 公 司 網 站「投 資 者 關 係」一 欄 或 ...

選擇公司通訊之收取方式及語言版本 為響應環保以提升與 閣下的溝通效率及節省印刷及郵遞費用，Wai Yuen Tong Medicine Holdings Limited（位元堂藥業控股有限公司*）（「本公司」）鼓勵及建議 閣下選擇收取於本公司網站 www.wyth.net本公司所有日後刊載之公司通訊（「公司通訊」）（「網上版本」）以代替印刷本。公司通訊 即本公司已刊發或將予刊發以供 閣下參照或採取行動之任何文件，包括但不限於：(a)董事會報 告、年度賬目連同獨立核數師報告及（如適用）財務摘要報告；(b)中期報告及（如適用）中期摘要報 告；(c)會議通告；(d)上市文件；(e)通函；及(f)代表委任表格。 根據香港聯合交易所有限公司（「聯交所」）證券上市規則第2.07A及2.07B條及遵守本公司的公司細 則，請 閣下填妥及簽署隨函附奉的回條（「回 條」），並將其寄回或親身交回本公司之香港股份過 戶及轉讓登記分處（「香港股份過戶登記分處」）卓佳證券登記有限公司（地址為香港夏愨道16號 遠 東金融中心17樓）或電郵至897-ecom@vistra.com。 倘本公司於二零二六年一月二十二日前尚未收到 閣下已填寫及簽 ...

謹此通知 閣下，Wai Yuen Tong Medicine Holdings Limited（位元堂藥業控股有限公司*）（「本公司」）之下述公司 通 訊（「本次公司通訊」）之英文及中文版本，現已於本公司網站www.wyth.net及香港聯合交易所有限公司（「聯 交 所」）網 站 www.hkexnews.hk登載；或 閣下所選擇之本次公司通訊之印刷本已隨函附上（如 閣下已選擇接 收本公司的公司通訊印刷版）： WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位元堂藥業控股有限公司 *） （於百慕達註冊成立之有限公司） （股份代號：897） 各位現有登記股東： 於本公司網站刊登公司通訊之通知 附註： 公司通訊指本公司已刊發或將予刊發以供本公司證券持有人參照或採取行動之任何文件，包括但不限於：(a)董事會報告、年度賬 目連同獨立核數師報告及（如適用）財務摘要報告；(b)中期報告及（如適用）中期摘要報告；(c)會議通告；(d)上市文件；(e)通函；及 (f)代表委任表格。 * 僅供識別 截至二零二五年九月三十日止六個月的中期報告 請於本公司網站「投資者關係」一欄或聯交所網站內或參考 ...

Content 目錄 C 錄 | CORPORATE INFORMATION | 公司資料 | 2 | | --- | --- | --- | | INTERIM DIVIDEND | 中期股息 | 5 | | MANAGEMENT DISCUSSION AND ANALYSIS | 管理層討論及分析 | 5 | | DISCLOSURE OF INTERESTS | 權益披露 | 14 | | SHARE OPTION SCHEME | 購股權計劃 | 20 | | CORPORATE GOVERNANCE AND OTHER INFORMATION | 企業管治及其他資料 | 23 | | CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR | 簡明綜合損益及 | 25 | | LOSS AND OTHER COMPREHENSIVE INCOME | 其他全面收益表 | | | CONDENSED CONSOLIDATED STATEMENT OF | 簡明綜合財務狀況表 | 28 | | FINANCIAL POSITION | | | | CONDENSED ...

Group 1 - Xiamen Airport is planning to acquire 100% equity of Xiamen Zhaoxiang Technology Co., Ltd., a wholly-owned subsidiary of its controlling shareholder, Xiamen Xiangye Group, using its own funds [2][4] - The acquisition aims to extend the company's business into the civil aviation intelligence sector, responding to the planned closure of Xiamen Gaoqi International Airport by the end of 2026 [2][4][5] - Zhaoxiang Technology focuses on civil aviation information technology, smart airport system construction and operation, and building intelligence, covering areas such as civil aviation operations, logistics, safety, and management [6][4] Group 2 - Xiamen Airport's main business is divided into aviation-related and non-aviation-related operations, with aviation-related operations including passenger and cargo services [8] - In November, Xiamen Airport reported a passenger throughput of 2.3195 million, a year-on-year decrease of 1.33%, and a cargo and mail throughput of 30,600 tons, down 13.25% year-on-year [8] - For the first three quarters of the year, Xiamen Airport achieved a revenue of 1.523 billion yuan, a year-on-year increase of 7.21%, and a net profit attributable to shareholders of 384 million yuan, up 3.53% year-on-year [8][9]

【导读】厦门空港筹划收购兆翔科技100%股权 12月9日，厦门空港（600897）发布公告称，公司正在筹划以自有资金收购公司控股股东厦门翔业集团有限公司（以下简称翔业集团）的全资子公司厦门 兆翔智能科技有限公司（以下简称兆翔科技）100%股权。本次收购完成后，上市公司的业务将向民航智能化领域延伸。 筹划收购兆翔科技100%股权 12月9日，厦门空港发布股票交易异常波动公告称，根据厦门市规划部署，厦门翔安国际机场计划于2026年底正式投入使用，厦门空港所运营的厦门高崎 国际机场将同步关闭，届时不再作为民用运输机场使用。 厦门空港曾在2025年中报中提到，受贸易、关税、汇率、航材、运力、油料、高铁等综合影响，维持民航增速存在一定的不确定性。 业绩方面，今年前三季度，厦门空港实现营业收入15.23亿元，同比增长7.21%；归属于母公司所有者的净利润为3.84亿元，同比增长3.53%。 为积极应对厦门高崎国际机场转场后上市公司机场主业持续经营存在的不确定性，同时积极响应国家鼓励上市公司向新质生产力方向转型升级的号召，公 司正在筹划以自有资金收购公司控股股东翔业集团的全资子公司兆翔科技100%股权。 经初步研究测算，本 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0. ...

Core Insights - The company, 位元堂 (00897), reported a revenue of approximately HKD 323 million for the six months ending September 30, 2025, representing a year-on-year decrease of 6.93% [1] - The profit attributable to the company's owners was HKD 2.772 million, a significant decline of 88.3% compared to HKD 23.701 million in the same period last year [1] - Earnings per share were reported at HKD 0.25 [1] Revenue Performance - The decrease in revenue is primarily attributed to weakened sales performance in traditional Chinese medicine, Western medicine, and health food products [1]

Core Viewpoint - The company reported a year-on-year decline in total revenue of approximately 6.9% to about HKD 323 million for the six months ending September 30, 2025, primarily due to weakened sales performance in traditional Chinese medicine, Western medicine, and health food products [1] Financial Performance - The company recorded a profit attributable to shareholders of approximately HKD 2.8 million, a significant decrease from approximately HKD 23.7 million for the same period ending September 30, 2024 [1] - Earnings per share were reported at HKD 0.025 [1] Market and Sales Dynamics - The decline in revenue was attributed to weak consumer sentiment in the retail market, leading to a reduction in gross profit and a significant drop in net gains from property sales, as well as a decrease in fair value gains from investment properties [1] Product Innovation and Marketing - The company continues to commit to product innovation, successfully launching a marketing campaign combining outdoor and digital promotions for its popular health product, which has seen significant sales growth [1] - New marketing campaigns are planned for flagship products such as An Gong Niu Huang Wan and Hou Zao Chu Tan San for the upcoming autumn and winter seasons [1] Regulatory Developments - The company has been closely collaborating with relevant Chinese authorities following the announcement of simplified approval processes for traditional Chinese medicine in the Greater Bay Area [1] - The company announced that Hou Zao Chu Tan San has been approved as the first OTC product in Hong Kong under this new process, which will allow millions of consumers in mainland China to access the product conveniently starting next year [1]

Core Insights - The company reported a revenue of approximately HKD 323 million for the six months ending September 30, 2025, representing a year-on-year decrease of 6.93% [1] - The profit attributable to the parent company was HKD 2.772 million, a significant decline of 88.3% compared to HKD 23.701 million in the same period last year [1] - Earnings per share were reported at HKD 0.025 [1] Revenue Performance - The decrease in revenue is primarily attributed to weakened sales performance in traditional Chinese medicine, Western medicine, and health food products [1]